Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11924 |
M3258
LMP7-IN-1 |
Proteasome | Proteases/Proteasome; Ubiquitination |
LMP7-IN-1 may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer, is an inhibitor of immunoproteasome (LMP7). | |||
T81921 |
LMP7-IN-2
|
||
LMP7-IN-2, 作为LMP7抑制剂,适用于相关炎症性疾病与失调的治疗。 | |||
T37420 |
Ac-ANW-AMC
Ac-ANW-AMC,Ac-Ala-Asn-Trp-AMC |
||
Ac-ANW-AMC is a fluorogenic substrate for the β5i/LMP7 subunit of the 20S immunoproteasome. [1] Upon cleavage, 7-amino-4-methylcoumarin (AMC) is released and its fluorescence can be used to quantify the activity of the β5i/LMP7 subunit of the 20S immunoproteasome. AMC displays excitation/emission maxima of 340-360/440-460 nm, respectively. Reference[1]. Winter, M.B., La Greca, F., Arastu-Kapur, S., et al. Immunoproteasome functions explained by divergence in cleavage specificity and regulation. ... | |||
T37419 | Zetomipzomib | ||
KZR-616, a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. KZR-616 has the potential for the research of multiple autoimmune diseases[1][2]. KZR-616 also inhibits MECL-1 subunit (IC50=623 nM) and constitutive proteasome β5 subunit (IC50=688 nM). KZR-616 maintains LMP7 and LMP2 selective inhibition in MOLT-4 cells. KZR-616 (250 nM) shows a comparable cytokine inhib... |